Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets

Nature Medicine

Volumn 18, Issue 1, 2012, Pages 153-158

  Jiang, Mali ^a   Wang, Jiawei ^a,b   Fu, Jinrong ^a   Du, Lin ^c   Jeong, Hyunkyung ^d   West, Tim ^e   Xiang, Lan ^a   Peng, Qi ^a   Hou, Zhipeng ^a   Cai, Huan ^f   Seredenina, Tamara ^g   Arbez, Nicolas ^a   Zhu, Shanshan ^a   Sommers, Katherine ^a   Qian, Jennifer ^a   Zhang, Jiangyang ^a   Mori, Susumu ^a   Yang, X William ^h   Tamashiro, Kellie L K ^a   Aja, Susan ^a   Moran, Timothy H ^a   Luthi Carter, Ruth ^g   Martin, Bronwen ^f   Maudsley, Stuart ⁱ   Mattson, Mark P ⁱ   Cichewicz, Robert H ^c   Ross, Christopher A ^a   Holtzman, David M ^e   Krainc, Dimitri ^d   Duan, Wenzhen ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g EPFL   (Switzerland)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; HUNTINGTIN; HYDROLASE; PHOSPHOPROTEIN DARPP 32; PROTEIN P53; SIRTUIN 1; SIRTUIN 1 DEACETYLASE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN NERVE CELL; CALORIC RESTRICTION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DEACETYLATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HUNTINGTON CHOREA; MALE; METABOLIC DISORDER; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MICE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RATS; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; SIRTUIN 1;

MAMMALIA; MUS;

EID: 84855544817     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2558     Document Type: Article

References (41)

1. Duan, W. et al. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. USA 100, 2911-2916 (2003). (Pubitemid 36297597)
2. Ross, C.A. & Thompson, L.M. Transcription meets metabolism in neurodegeneration. Nat. Med. 12, 1239-1241 (2006). (Pubitemid 44706921)
3. McGill, J.K. & Beal, M.F. PGC-1β, a new therapeutic target in Huntington's disease? Cell 127, 465-468 (2006). (Pubitemid 44647438)
4. Browne, S.E. & Beal, M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 8, 2061-2073 (2006). (Pubitemid 46489631)
5. Haigis, M.C. & Sinclair, D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253-295 (2010).
6. de Oliveira, R.M., Pais, T.F. & Outeiro, T.F. Sirtuins: common targets in aging and in neurodegeneration. Curr. Drug Targets 11, 1270-1280 (2010).
7. Parker, J.A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37, 349-350 (2005).
8. Pallos, J. et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17, 3767-3775 (2008).
9. Satoh, A. et al. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. J. Neurosci. 30, 10220-10232 (2010).
10. Schilling, G. et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407 (1999). (Pubitemid 29097327)
11. Zhang, J. et al. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 49, 2340-2351 (2010).
12. Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182-6195 (2008).
13. Menalled, L. et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 35, 319-336 (2009).
14. Li, M., Huang, Y., Ma, A.A., Lin, E. & Diamond, M.I. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis. 36, 413-420 (2009).
15. Chopra, V. et al. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. USA 104, 16685-16689 (2007). (Pubitemid 350211077)
16. Chou, S.Y. et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93, 310-320 (2005).
17. Simmons, D.A., Mehta, R.A., Lauterborn, J.C., Gall, C.M. & Lynch, G. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol. Dis. 41, 436-444 (2011).
18. Jeong, H. et al. Sirt1 mediates neurprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. advance online publication, doi:10.1038/nm.2558 (18 December 2011).
19. Cohen, E. & Dillin, A. The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat. Rev. Neurosci. 9, 759-767 (2008).
20. Bibb, J.A. et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA 97, 6809-6814 (2000). (Pubitemid 30412796)
21. Greengard, P., Allen, P.B. & Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435-447 (1999). (Pubitemid 29359916)
22. Fienberg, A.A. et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281, 838-842 (1998). (Pubitemid 28376047)
23. Vonsattel, J.P. et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577 (1985).
24. de la Monte, S.M., Vonsattel, J.P. & Richardson, E.P. Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47, 516-525 (1988).
25. Zuccato, C. & Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311-322 (2009).
26. Nakagawa, T. et al. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes Metab. Res. Rev. 18, 185-191 (2002). (Pubitemid 34778381)
27. Ivkovic, S., Polonskaia, O., Farinas, I. & Ehrlich, M.E. Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro. Neuroscience 79, 509-516 (1997). (Pubitemid 27232407)
28. Wang, W. et al. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 20, 500-508 (2005). (Pubitemid 41476276)
29. Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179 (2007). (Pubitemid 47057498)
30. Rodgers, J.T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1βand SIRT1. Nature 434, 113-118 (2005). (Pubitemid 40349395)
31. Luo, J. et al. Negative control of p53 by Sir2promotes cell survival under stress. Cell 107, 137-148 (2001). (Pubitemid 33035941)
32. Morris, B.J. A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. J. Hypertens. 23, 1285-1309 (2005). (Pubitemid 40933947)
33. Kops, G.J. et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316-321 (2002).
34. Peng, K. et al. Knockdown of FoxO3a induces increased neuronal apoptosis during embryonic development in zebrafish. Neurosci. Lett. 484, 98-103 (2010).
35. Mojsilovic-Petrovic, J. et al. FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J. Neurosci. 29, 8236-8247 (2009).
36. Cui, L. et al. Transcriptional repression of PGC-1βby mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59-69 (2006). (Pubitemid 44466642)
37. Chaturvedi, R.K. et al. Impairment of PGC-1βexpression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet. 19, 3190-3205 (2010).
38. Weydt, P. et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1βin Huntington's disease neurodegeneration. Cell Metab. 4, 349-362 (2006). (Pubitemid 44645069)
39. Tran, H. et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530-534 (2002). (Pubitemid 34408672)
40. Puigserver, P. et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1βinteraction. Nature 423, 550-555 (2003). (Pubitemid 36648580)
41. Milne, J.C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007). (Pubitemid 350207685)